We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00600925
Recruitment Status : Completed
First Posted : January 25, 2008
Results First Posted : September 24, 2021
Last Update Posted : September 24, 2021
Duke University
Premier Research Group plc
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine whether the gentamicin-collagen sponge is safe and effective for preventing surgical wound infections in patients undergoing colorectal surgery.

Condition or disease Intervention/treatment Phase
Colorectal Surgery Surgical Wound Infection Drug: gentamicin-collagen sponge dipped in saline Phase 3

Detailed Description:

Surgical wound infection (SWI) is a significant problem in colorectal surgery. Despite the use of routine bowel preparation and prophylactic antibiotics the incidence of SWI is at least 15% in patients undergoing colorectal surgical procedures.Therefore, there is a long unmet need for an intervention that can reduce the incidence and severity of SWIs in patients undergoing colorectal surgery.

Gentamicin is an antibiotic that is effective in treating certain kinds of infection. Collagen is a protein that is found in all mammals. The gentamicin-collagen sponge is a thin flat sponge made out of collagen that comes from cow tendons and containing gentamicin. When inserted into a surgical site, the collagen breaks down and the gentamicin is released at the site but very little is absorbed into the blood stream. The high levels of antibiotic at the surgical site may prevent an infection at the surgical site.

Outside of the United States more than 3,500 subjects have received treatment in clinical studies with the gentamicin-collagen sponge, primarily for orthopedic, intraabdominal, and cardiothoracic surgeries or wound infections following surgical procedures or traumatic events.

In this study, all subjects will be given treatment that is normally given to prevent surgical infections. For subjects randomly assigned to the gentamicin-collagen sponge treatment group, 2 sponges will be inserted into the surgical wound immediately before the surgeon closes it. The control group will receive no collagen sponge.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 602 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Controlled, Phase 3 Study of Gentamicin-Collagen Sponge in General Surgical Subjects at Higher Risk for Surgical Wound Infection
Study Start Date : January 2008
Actual Primary Completion Date : March 2009
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Insertion of 2 gentamicin-collagen sponges before closure of the laparotomy (each 10 x 10 cm sponge contains 280 mg collagen and 130 mg gentamicin).
Drug: gentamicin-collagen sponge dipped in saline
2 gentamicin-collagen sponges inserted before closure of the laparotomy

No Intervention: 2
Standard of care, ie, no gentamicin-collagen sponge.

Primary Outcome Measures :
  1. Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 60 [ Time Frame: assessed at Postop Day 1, 2, 3, 7, 30 & 60 ]
    Primarily, efficacy will be evaluated by a comparison between the 2 study groups of the incidence of surgical wound infections (involving the laparotomy incision) that occur within the period from surgery through postop day 60.

Secondary Outcome Measures :
  1. Number of Participants Who Had Superficial Incisional Surgical Wound Infection [ Time Frame: assessed at Postop Day 1, 2, 3, 7, 30 & 60 ]
    Number of Participants who had superficial incisional surgical wound infection, based on CDC criteria adjudicated by an independent blinded committee

  2. The Effect of the Gentamicin-collagen Sponge on the Proportion of Patients With Deep Incisional Surgical Wound Infection [ Time Frame: assessed at Postop Day 1, 2, 3, 7, 30 & 60 ]
    The proportion of subjects who had deep incisional SWI, based on Centers for Disease Control and Prevention (CDC) criteria adjudicated by an independent blinded committee

  3. The Effect of the Gentamicin-collagen Sponge on the ASEPSIS Score [ Time Frame: Days 3, 4, 5, 6, and 7 (or discharge if earlier) and then questionnaire/phone call on post-operative Days 30 and 60. ]
    Mean (SD) ASEPSIS Score Through 60 Days Postoperatively - brief assessment of surgical wound on post-operative Days 3, 4, 5, 6, and 7 (or discharge if earlier) and then questionnaire/phone call on post-operative Days 30 and 60. Score from each time point is added up and the mean score is reported. Used to compare antibiotic regimens for their effectiveness in preventing or treating wound sepsis, well-defined criteria for outcome are needed. A method of assessing wound healing has been devised that defines carefully the characteristics to be considered and how they are to be awarded points. Objective criteria are also included in the assessment. Points are given for the need for Additional treatment, the presence of Serous discharge, Erythema, Purulent exudate, and Separation of the deep tissues, the Isolation of bacteria, and the duration of inpatient Stay (ASEPSIS). The higher the points the worse outcome. Maximum Points would be 60. Minimum points would be 0

  4. The Effect of the Gentamicin-collagen Sponge on Length of Hospital Stay Postoperatively. [ Time Frame: Immediate post operative period ]
  5. Number of Participants Who Were Rehospitalized for Surgical Wound Infection Within 60 Days Post-operatively [ Time Frame: Through 60 days after surgery ]
    The effect of the gentamicin-collagen sponge on rehospitalization for surgical wound infection.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Scheduled to undergo nonemergent colon and/or rectal surgical procedures involving a laparotomy incision of at least 7 cm in length or greater. List of eligible procedures: Left Hemicolectomy, Transverse Colectomy, Segmental/Sleeve Left Colon Resection, Total Abdominal Colectomy With Ileorectal Anastomosis, Total Abdominal Colectomy With Ileostomy, Total Abdominal Proctocolectomy (Portion Of Specimen To Be Extracted Via Laparotomy), Low Anterior Resection, Sigmoid Resection, Non-Emergent Hartmann's Procedure, Colotomy With Polypectomy Distal To Hepatic Flexure, Colostomy Takedown Through Laparotomy (Not Peristomal) Incision, Ileo-Pouch Anal Anastomosis, Abdominal Perineal Resection of the Rectum
  • Have the capacity to understand and sign an informed consent form.
  • Are male or female and > 18 years of age.
  • If female, be postmenopausal (no menstrual period for a minimum of 1 year), or surgically sterilized (does not have a uterus or has had bilateral tubal ligation). Females of child-bearing potential must have a negative serum pregnancy test on entry in the study, and agree to use adequate birth control during the study and for 60 days after the administration of study agent.
  • Agree to be available for evaluation from baseline until final evaluation at 60 days postsurgery.

Exclusion Criteria:

  • Known history of hypersensitivity to gentamicin or bovine collagen.
  • Undergoing emergency surgery (urgent surgery is allowed if informed consent is obtained and the study procedures can be performed). Emergency surgery includes cases where standard bowel preparation and other preoperative assessments cannot be done.
  • Undergoing a significant concomitant surgical procedure (e.g., hysterectomy). The following concomitant procedures are allowed: appendectomy, cholecystectomy, oophorectomy, liver biopsy/wedge resection (but not liver resection).
  • Undergoing a laparoscopic, laparoscopic-assisted, or other minimally invasive surgical approach involving a laparotomy incision less than 7 cm.
  • History of prior laparotomy within the last 60 days of this planned procedure.
  • Planned to undergo a second laparotomy or colorectal surgical procedure (e.g. colostomy or ileostomy takedown) within 60 days of this planned first procedure.
  • Evidence preoperatively of any of the following: sepsis, severe sepsis, or septic shock (note that SIRS alone is not an exclusion criterion)
  • Current abdominal wall infection/surgical site infection from previous laparotomy/laparoscopy or for any reason.
  • Receiving antibiotic therapy within the 1 week prior to the date of surgery.
  • Preoperative evaluation suggests intra-abdominal process that might preclude full closure of the skin.
  • History of ongoing treatment (e.g. chemotherapy, radiation) for non-colorectal cancer.
  • Recent history of significant drug or alcohol abuse.
  • Preoperative prothrombin time (PT) > 1.5 times upper limit of normal
  • Pregnant, lactating, or of childbearing potential not practicing a birth control method with a high degree of reliability
  • Postsurgical life expectancy ≤ 60 days, in the investigator's or sponsor's opinion.
  • Refusal to accept medically indicated blood products.
  • Previous participation in this or any other active Innocoll Gentamicin-Collagen Sponge study.
  • Participation within 30 days before the start of this study in any experimental drug or device study, or currently participating in a study in which the administration of investigational drug or device within 60 days is anticipated.
  • Surgeon does not believe that it will be possible to insert 2 sponges above the fascia in the patient (e.g. in a very thin patient planned to have a small incision)
  • Patients with anterior abdominal wall mesh that is not planned to be completely removed during the planned procedure.
  • Presence of prosthetic cardiac valve.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00600925

Layout table for location information
United States, Alabama
Florence, Alabama, United States
Mobile, Alabama, United States
United States, California
Laguna Hills, California, United States
Los Angeles, California, United States
Stanford, California, United States
United States, Colorado
Aurora, Colorado, United States
Denver, Colorado, United States
United States, Florida
Tampa, Florida, United States
Weston, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Kentucky
Louisville, Kentucky, United States
United States, Louisiana
New Orleans, Louisiana, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Michigan
Detroit, Michigan, United States
United States, Minnesota
Duluth, Minnesota, United States
Minneapolis, Minnesota, United States
United States, Missouri
Saint Louis, Missouri, United States
United States, New York
Albany, New York, United States
Brooklyn, New York, United States
New York, New York, United States
Syracuse, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
Durham, North Carolina, United States
Greensboro, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Houston, Texas, United States
Temple, Texas, United States
United States, Vermont
Burlington, Vermont, United States
United States, Washington
Seattle, Washington, United States
Tacoma, Washington, United States
Sponsors and Collaborators
Duke University
Premier Research Group plc
Layout table for investigator information
Study Director: David Prior Innocoll
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Innocoll
ClinicalTrials.gov Identifier: NCT00600925    
Obsolete Identifiers: NCT01150773
Other Study ID Numbers: INN-SWI-002
First Posted: January 25, 2008    Key Record Dates
Results First Posted: September 24, 2021
Last Update Posted: September 24, 2021
Last Verified: September 2021
Keywords provided by Innocoll:
Colorectal surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Wound Infection
Surgical Wound Infection
Wounds and Injuries
Surgical Wound
Disease Attributes
Pathologic Processes
Postoperative Complications
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action